Tamoxifen

Drug information

• Monograph (BC Cancer)
• Trade Name: Novaldex
• Novaldex and Novaldex Side Effects Information

Indication

Breast Cancer

Adjuvant therapy

• Tamoxifen 20 mg po qd x 5 years
• Tamoxifen 20 mg po qd + Goserelin 3.6 mg sc qm

References

LHRH-agonists in Early Breast Cancer Overview Group. Use of luteinising-hormone-releasing hormone agonists as adjuvant treatment in premenopausal patients with hormone-receptor-positive breast cancer: a meta-analysis of individual patient data from randomised adjuvant trials. Lancet 2007; 369:1711

Metastatic cancer

• Tamoxifen 20 mg po qd

References

Ingle, JN et al. Randomized clinical trial of diethylstilbestrol versus tamoxifen in postmenopausal women with advanced breast cancer. N Engl J Med 1981; 304:16

Endometrial Cancer

Hormonal therapy for stage IVB (metastatic) cancer

• Tamoxifen 20 mg po bid

References

Carlson, JA Jr et al. Tamoxifen and endometrial carcinoma: alterations in estrogen and progesterone receptors in untreated patients and combination hormonal therapy in advanced neoplasia. Am J Obstet Gynecol 1984; 149:149

Ovarian Epithelial Cancer

Chemotherapy for recurrent or metastatic cancer

• Tamoxifen 20 mg po bid

References

Markman M et al. Tamoxifen in platinum-refractory ovarian cancer: a Gynecologic Oncol0gy Group Ancillary Report. Gynecol Oncol 1996; 62:4

Ahlgren JD et al. Hormonal palliation of chemoresistant ovarian cancer: three consecutive phase II trials of the Mid-Atlantic Oncology Program. J Clin Oncol 2003; 11:1957

Hatch KD et al. Responsiveness of patients with advanced ovarian carcinoma to tamoxifen. A Gynecologic Oncology Group study of second-line therapy in 105 patients. Cancer 1991; 68:269